CAS: 212127-83-8; Tert-Butyl 3-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-2,5-Dihydro-1H-Pyrrole-1-Carboxylate

相似化合物

1779540-37-2 1799330-80-5 2227133-31-3

上下游产品

(1-(Phenylmethyl)-3-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-yl)-2,5-Dihydro-1H-Pyrrole) 439813-70-4

📜二碳酸二叔丁酯置于rucl2(1,3-Dimesityl-Imidazolidin-2-yl)(Pcy3)(=chph),叔丁基锂体系中,用 四氢呋喃,乙醚,二氯甲烷,正戊烷 用作溶剂,化学反应 4.4H,反应生成1-叔丁氧羰基-2,5-二氢-1H-吡咯-3-硼酸频哪醇酯
参考文献:杂双环[n.1.0]烷烃-1-基三氟硼酸酯的多谱合成
标题:杂双环[n.1.0]烷烃-1-基三氟硼酸酯的多谱合成
摘要:本文描述了依赖于有效的4-5步反应序列的oxa-和氮杂双环[ N .1.0]烷烃-1-基三氟硼酸酯的合成方法.一次即可获得高达50 G的标题化合物(总收率10-41%).
Doi:10.1002/ejoc.202000977

专利信息

专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

专利号:US-9549921-B2
优先权日:2013-06-24
标 题:Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C
发明人：HE SHUWEN; LAI ZHONG; DAI XING; XIAO DONG; LONDON CLARE; ZORN NICOLAS; NARGUND RAVI; PALANI ANANDAN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD
权利人:HE SHUWEN; LAI ZHONG; DAI XING; XIAO DONG; LONDON CLARE; ZORN NICOLAS; NARGUND RAVI; PALANI ANANDAN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD; MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I)

专利号:US-9839642-B2
优先权日:2014-05-09
标 题:Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors
发明人：TANG HAIFENG; YANG SHU-WEI; MANDAL MIHIR; SU JING; LI GUOQING; PAN WEIDONG; TANG HAIQUN; DEJESUS REYNALDA; PAN JIANPING; HAGMANN WILLIAM; DING FA-XIANG; XIAO LI; PASTERNAK ALEXANDER; HUANG YUHUA; DONG SHUZHI; YANG DEXI
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

专利号:US-11459325-B2
优先权日:2018-01-31
标题:Heterocyclic compound
发明人：TANAKA YUTA; OHASHI TOMOHIRO; IKEDA ZENICHI; TANAKA YUTA; PÃœNNER FLORIAN; YAMAMOTO TAKESHI; KAKEGAWA KEIKO; KIKUCHI FUMIAKI; MORISHITA NAO; KASAHARA TAKAHITO; SETO MASAKI; NAKAMURA MINORU; TAKAMI KAZUAKI; MURAKAMI MASATAKA; DAINI MASAKI; MIKAMI SATOSHI; SASAKI MINORU
权利人:TAKEDA PHARMACEUTICALS CO
摘要:The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. n The present invention relates to a compound represented by the formula (I): n nwherein each symbol is as described in the specification, or a salt thereof.

专利号:US-10227344-B2
优先权日:2016-06-24
标题 :CK2 inhibitors, compositions and methods thereof
发明人：WEBBER STEPHEN E; TAO XUELIANG; BRIN ELENA
权利人:POLARIS PHARMACEUTICALS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. n nFor Formula (I) compounds R 1 , R 2 , R 3 , Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.